Portfolio | Terns Pharmaceuticals与上海拓臻生物完成8千万美元B轮融资，开发NASH和癌症药物

筹集资金将用于支持 NASH 候选药物的临床及临床前研发

由维梧资本（Vivo Capital）和奥博资本（OrbiMed）领投，德诚资本（Decheng Capital）跟投

A轮投资人礼来亚洲基金（Lilly Asia Ventures）亦共同参与B轮投资

加州圣马特奥和中国上海--(BUSINESS WIRE)--(美国商业资讯)--Terns Pharmaceuticals Inc. 与上海拓臻生物科技有限公司是一家全球性生物制药公司，致力于治疗非酒精性脂肪性肝炎（NASH）和癌症的口服小分子创新药物的研发，该公司于今日宣布完成 8000 万美元 B 轮融资。

“公司自去年成立以来，我们一直在努力推进各项重点研发项目，以进一步深化公司的长远发展战略，致力于向中国及全球缺乏有效药物的广大患者提供治疗新药。此轮融资将为公司战略的持续推进提供有效的资金保障。” Terns 的总裁兼首席执行官 Weidong Zhong 博士表示， “我们对团队在各个项目上已取得的进展感到非常振奋。我们的重点项目 TERN-101 和 TERN-201 将于2019年上半年如期进入临床阶段，其他 NASH 项目也正在快速地向临床前开发阶段推进。我们的长远目标是为 NASH 和肝纤维化患者开发出安全有效的联合疗法，我们至今取得的进展让我们离这一目标又近了一步。我们十分感激新的投资者与现有投资者对我们的信心和热忱。”

“Terns 综合利用其在疾病生物学、药物化学领域的专业技能以及在中国进行临床开发的经验和能力，建立了高质量且多样化的 NASH 药物研发管线，非常有希望为患者带来有潜力的新药。” 维梧资本管理合伙人、全球联席 CEO 付山先生表示， “我们对能与其他优秀投资者共同参与这一难得的投资机会感到兴奋，并且对 Terns 采取的全新战略充满信心。Vivo 在 NASH 方面有丰富的投资经验，相信我们对公司未来的发展将带来更多的价值。”

“Terns 采用全球或区域特定的研发战略来推进新的 NASH 临床治疗方法，此战略具有独特的竞争力。自公司近期成立以来，团队已经取得了巨大的进展，这令我们对其未来持续发展的能力充满信心。” 奥博资本管理合伙人、Carl Gordon 博士表示 。

此轮融资由新投资者维梧资本（Vivo Capital）和奥博资本（OrbiMed）共同领投，新投资者德诚资本（Decheng Capital）跟投；现有投资者礼来亚洲基金（Lilly Asia Ventures）亦参与本轮融资，持续支持公司长远发展。

关于 Terns Pharmaceuticals 与上海拓臻生物科技有限公司

Terns Pharmaceuticals 是一家全球性生物制药公司，致力于治疗肝病和癌症的分子靶向、口服小分子创新药物的研发，在加州圣马特奥和中国上海（上海拓臻生物科技有限公司 Terns China Biotechnology）设有总部。公司综合其在疾病生物学、药物化学领域的专项技能以及在中国进行临床开发的经验和能力，推进其不断拓展的候选药物管线，这些候选药物经过优化，可有效作用于经过临床或大量临床前验证的靶点。公司采用具有高资本效率的药物研发模式，致力于通过具有全球及地区针对性的临床开发项目向全球缺乏有效药物的广大患者提供治疗新药。欲了解进一步信息，请访问www.TernsPharma.com及http://www.ternspharma.com.cn/

美国媒体联系方式

Cory Tromblee

617-571-7220 

中国媒体联系方式:

Eddy Wu

[phone]

---

附英文新闻：

Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

Proceeds to Support Development of Clinical and Preclinical NASH Candidates

Financing Led by Vivo Capital and OrbiMed, joined by Decheng Capital

Lilly Asia Ventures, the Series A investor, also investing in the Series B round

SAN MATEO, Calif. & SHANGHAI-- (BUSINESS WIRE) -- Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced the closing of an $80 million Series B financing.

"Since we launched the company a short time ago, we have been working diligently to advance our key programs and continue executing on our strategy to bring innovative therapeutics to underserved patients globally, and with this financing we are well positioned to continue to execute on that mission," said Weidong Zhong, Ph.D., President and CEO of Terns. "We are excited about the progress we’ve made on our clinical and preclinical programs. Our lead programs TERN-101 and TERN-201 are on track to enter the clinic in the first half of 2019 and additional NASH programs are advancing rapidly towards preclinical development. The progress so far has put us one step closer to our goal of discovering effective and safe combination therapies for patients with NASH and liver fibrosis. We are grateful for the confidence and enthusiasm coming from our new and existing investors."

"Terns leverages a combination of expertise in disease biology, medicinal chemistry, and extensive clinical development capabilities to build its high-quality and diverse pipeline for the treatment of NASH, offering an incredible opportunity to bring potentially promising new therapies to patients," said Mr. Shan Fu, Vivo Capital's Managing Partner and Co-CEO. "We are excited to be co-leading a great group of investors and are believers in the novel approach Terns is taking. Vivo has substantial investment experience in the development of therapeutics for NASH.  We believe that we will add value to the company in terms of its future development."

"Their approach of adopting global or region-specific development strategies for advancing new clinical-stage therapeutics is unique, and they’ve made tremendous progress since they recently launched," said Carl Gordon, Ph.D., Managing Partner of OrbiMed. "This gives us great confidence in their ability to successfully sustain that forward trajectory."

The financing was led by new investors Vivo Capital and OrbiMed, joined by new investor Decheng Capital; existing investor Lilly Asia Ventures also participated to provide continuous support.

About Terns Pharmaceuticals

Based in San Mateo, CA., and Shanghai, China, Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly targeted, oral,small-molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology, medicinal chemistry and extensive clinical development capabilities in China to advance its growing pipeline of drug candidates that are optimized against clinically validated targets or targets that have significant preclinical validation. Using a capital-efficient drug discovery model, the company’s mission is to bring promising new therapies topatients in underserved markets via global and region-specific development programs. For more information, visit www.TernsPharma.com.

US Media Contact:

Cory Tromblee

617-571-7220

China Media Contact:

Eddy Wu

+ 86 180 1631 1449

Source: Terns Pharmaceuticals Inc.

相关新闻：

近期文章

Portfolio公司新闻

行业动态

原创

欢迎关注：